Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity

Ann Oncol. 2016 Apr;27(4):748-50. doi: 10.1093/annonc/mdw021. Epub 2016 Jan 19.

Authors

M Takeda¹, K Sakai², K Okamoto³, H Hayashi³, K Tanaka³, T Shimizu³, K Nishio², K Nakagawa³

Affiliations

¹ Department of Medical Oncology takedamasa2004@yahoo.co.jp.
² Department of Genome Biology, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
³ Department of Medical Oncology.

PMID: 26787234
DOI: 10.1093/annonc/mdw021

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Drug Resistance, Neoplasm / genetics
Female
Genome, Human
High-Throughput Nucleotide Sequencing
Humans
Indoles / administration & dosage*
Middle Aged
Oncogene Proteins, Fusion / genetics
Proto-Oncogene Proteins c-ret / genetics*
Transcription Factors / genetics*

Substances

CCDC62 protein, human
Indoles
Oncogene Proteins, Fusion
Transcription Factors
Proto-Oncogene Proteins c-ret
RET protein, human
nintedanib